AI assistant
RENALYTIX PLC Director's Dealing 2023
7877_mrq_2023-11-23_d99f80ba-ce35-41c4-9ae7-2060cc8ebe3f.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 3917U
Renalytix PLC
23 November 2023
Renalytix plc
("Renalytix" or the "Company")
Grant of Share Options
LONDON and SALT LAKE CITY - November 23, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that the Board have granted options over a total of 380,000 ordinary shares of 0.25 pence each in the capital of the Company (the "Share Options") to the following individuals:
| Name | Position | Options granted |
| Christopher Mills | Non-Executive Chairman | 95,000 |
| Daniel Levangie | Non-Executive Director | 95,000 |
| Chirag Parikh | Non-Executive Director | 95,000 |
| Catherine Coste | Non-Executive Director | 95,000 |
The Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of £0.245 per ordinary share, being the closing price of the shares on the 17 November 2023.
All the Share Options granted one twelfth of the Share Options vest 3 months from the date of grant with one twelfth vesting quarterly after that, subject to the individuals remaining employed by the Company as Non-Executive Directors.
The issue of the Share Options are deemed to be related party transactions pursuant to AIM Rule 13 of the AIM Rules for Companies. The Company's directors (excluding those who are being awarded the Share Options) consider, having consulted with the Nominated Adviser, Stifel Nicolaus Europe Limited, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.
For further information, please contact:
| Renalytix plc | www.renalytix.com |
| James McCullough, CEO | Via Walbrook PR |
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 |
| Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea | |
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 |
| Gary Clarence / Shalin Bhamra | |
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] |
| Paul McManus / Alice Woodings | Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
| CapComm Partners | |
| Peter DeNardo | Tel: 415-389-6400 or [email protected] |
About Renalytix
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Christopher Mills | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Non-Executive Chairman | |||
| b) | Initial notification /Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Renalytix plc | |||
| b) | LEI | 213800NTOH3FK3WER551 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Options over ordinary shares of 0.25 pence each in the Company | |||
| Identification code | GB00BYWL4Y04 | ||||
| b) | Nature of the transaction | Grant of options over shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| £0.245 | 95,000 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | 95,000 | ||||
| - Price | £23,275 | ||||
| e) | Date of the transaction | 21 November 2023 | |||
| f) | Place of the transaction | Outside of trading venue - off market |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Dan Levangie | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Non-Executive Director | |||
| b) | Initial notification /Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Renalytix plc | |||
| b) | LEI | 213800NTOH3FK3WER551 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Options over ordinary shares of 0.25 pence each in the Company | |||
| Identification code | GB00BYWL4Y04 | ||||
| b) | Nature of the transaction | Grant of options over shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| £0.245 | 95,000 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | 95,000 | ||||
| - Price | £23,275 | ||||
| e) | Date of the transaction | 21 November 2023 | |||
| f) | Place of the transaction | Outside of trading venue - off market |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Chirag Parikh | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Non-Executive Director | |||
| b) | Initial notification /Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Renalytix plc | |||
| b) | LEI | 213800NTOH3FK3WER551 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Options over ordinary shares of 0.25 pence each in the Company | |||
| Identification code | GB00BYWL4Y04 | ||||
| b) | Nature of the transaction | Grant of options over shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| £0.245 | 95,000 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | 95,000 | ||||
| - Price | £23,275 | ||||
| e) | Date of the transaction | 21 November 2023 | |||
| f) | Place of the transaction | Outside of trading venue - off market |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Catherine Coste | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Non-Executive Director | |||
| b) | Initial notification /Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Renalytix plc | |||
| b) | LEI | 213800NTOH3FK3WER551 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Options over ordinary shares of 0.25 pence each in the Company | |||
| Identification code | GB00BYWL4Y04 | ||||
| b) | Nature of the transaction | Grant of options over shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| £0.245 | 95,000 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | 95,000 | ||||
| - Price | £23,275 | ||||
| e) | Date of the transaction | 21 November 2023 | |||
| f) | Place of the transaction | Outside of trading venue - off market |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFLLLLXFLBFBE